We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
13 own
8 watching
Current Price
$0.47
$0.01
(1.08%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
82.67M
52-Week High
3.23000
52-Week Low
0.41400
Average Volume
1.13M
Dividend Yield
--
P/E Ratio
--
Market Capitalization82.67M52-Week High3.2300052-Week Low0.41400Average Volume1.13MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
3 months ago
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks of patient follow-up SALT LAKE CITY, June 26, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene ...
Globe Newswire
3 months ago
Investment led byVivo Capitalwith participation fromSymBiosis,Acuta Capital Partners,AIGH Capital,Serrado Capital LLC,and other new biotech investors, with support from existing insiders$40 millionunderwritten public offering with up to an additionalpotential $130.8 millionin proceeds through future...
Globe Newswire
3 months ago
SALT LAKE CITY, June 16, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced ...
PR Newswire
6 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Clene Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Clene Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR...
Globe Newswire
6 months ago
SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$0.47
$0.01
(1.08%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.